Skip to content

TRMB: Held by 2 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›TRIMBLE INC. (TRMB)

TRIMBLE INC.

TRMB

Held by 2 specialist biotech funds

2 funds opened new positions. Short interest: 5.0% of float.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

3.0/10

2 funds opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 2 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Eventide Asset ManagementNew

Deerfield Management

AI Signal

Signal Note — TRMB | Eventide Asset Management | New Position

Trimble (TRMB) is not a biotech — it's a precision technology and industrial software company — so Eventide's initiation here likely reflects its broader values-aligned growth mandate rather than a drug pipeline thesis. The $962K new position is modest but notable given concurrent ownership by Deerfield Management, a healthcare-specialist fund that occasionally holds non-biotech names with digital health or AgTech adjacency, creating a two-fund convergence worth monitoring.

Unlock full AI analysis — 14-day free trial

2 quarters

Position Trend

Aug 14, 2025

$0

0 funds

Nov 14, 2025

$0

0 funds

Feb 17, 2026

$0

0 funds

May 15, 2026

$962K

1 fund

+45% total institutional value over 7 quarters

Short Interest

Short Shares

10.00M

Change

+44.7%

Days to Cover

3.4

% of Float

5.0%

Settlement

Jun 15, 2026

Short interest over 7 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Eventide Asset ManagementNEW POSITIONMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

7 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

PHGE1 fund ACAD1 fund AHCO1 fund ALEC1 fund ALNY1 fund ANNX1 fund ARWR1 fund SPRY1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: